Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
CSPC PHARMA's US Clinical Trial Application for Highly Selective MAT2A Inhibitor Approved
Recommend 4 Positive 3 Negative 5 |
||||
|
||||
|
A highly selective MAT2A inhibitor (SYH2039), a new Class 1 chemical drug developed by CSPC PHARMA (01093.HK), has been approved by the US Food and Drug Administration (FDA) to conduct clinical trials in the US, according to CSPC PHARMA's announcement. The product already obtained approval from the National Medical Products Administration of China (NMPA) to conduct clinical trials in China in March. AAStocks Financial News |
||||
Copied to Clipboard
 |
||||
